Prostate cancer markers and imaging for low-risk patients on active surveillance
Part of Cancer clinical trials.
This trial looks for new markers and advanced scans to better predict which low-risk prostate cancers might grow. If you have low-risk prostate cancer and are managing it with active surveillance, researchers want to see if PSMA-PET scans and tissue markers can give earlier warning of progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have low-risk prostate cancer (PSA 10 or less, tumor stage T2a or lower, and a Gleason grade group 1 biopsy).
- Your cancer must not have spread beyond the prostate (confirmed at enrollment).
- You cannot have had or be receiving hormone therapy (androgen deprivation therapy).
- You must be willing to have active surveillance as your management plan (not immediate treatment).
- You must be able to have a PSMA-PET scan (no pacemaker, no medical reason preventing it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special imaging test (PSMA PET/CT) to better see if men with low-risk prostate cancer are good candidates for active surveillance (monitoring instead of immediate treatment). It helps doctors decide if watching the cancer closely is safe.
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
This study checks whether a special prostate scan called PSMA PET-CT (along with standard monitoring scans) can help guide care while you are on “active surveillance” instead of immediate treatment. It may help doctors track low-risk prostate cancer changes more accurately over time.
This study checks whether people with a low chance of prostate cancer can be monitored closely without having an immediate prostate biopsy. It uses PSA blood tests and prostate MRI to sort who may safely wait.
This trial uses special MRI scans to help track low-risk prostate cancer while you stay on active surveillance (meaning no immediate treatment). It may help your care team better understand changes in the cancer over time.
This early-phase study tests a special PET-MRI scan using rhPSMA-73 to better detect prostate cancer areas in men who would otherwise choose active surveillance. It may help doctors see where (and how much) cancer is present before deciding on treatment.
Hear when a new Low Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.